CLEAR COPY OF CLAIMS

We claim:

1. A pharmaceutical composition comprising:

a) an effective amount of ledipasvir having the formula:



wherein the ledipasvir is substantially amorphous; and

b) an effective amount of sofosbuvir having the formula:



wherein the sofosbuvir is substantially crystalline, and further wherein the composition exhibits unexpected properties.

2. The pharmaceutical composition of claim 1, wherein the ledipasvir is formulated as a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer.

3. The pharmaceutical composition of claim 2, wherein the polymer is copovidone.

4. The pharmaceutical composition of claim 3, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion is about 1:1.

5. The pharmaceutical composition of claim 4, comprising

a) about 40% w/w of sofosbuvir and

b) about 18 %w/w of the solid dispersion.

6. The pharmaceutical composition of claim 5, further comprising

a) about 5 to about 25% w/w lactose monohydrate,

b) about 5 to about 25% w/w microcrystalline cellulose,

c) about 1 to about 10% w/w croscarmellose sodium,

d) about 0.5 to about 3% w/w colloidal silicon dioxide, and

e) about 0.1 to about 3% w/w magnesium stearate.

7. A pharmaceutical dosage form comprising the pharmaceutical composition of claim 1, comprising about 90 mg of ledipasvir and about 400 mg of sofosbuvir.

8. The pharmaceutical dosage form of claim 7, wherein the ledipasvir is formulated as a solid dispersion within a polymer matrix of copovidone.

9. The pharmaceutical dosage form of claim 8, wherein the amount of copovidone is about 90 mg.

10. The pharmaceutical dosage form of claim 9, further comprising:

(a) about 165 mg of lactose monohydrate;

(b) about 180 mg of microcrystalline cellulose;

(c) about 50 mg of croscarmellose sodium;

(d) about 10 mg of colloidal silicon dioxide; and

(e) about 15 mg of magnesium stearate.

11. The pharmaceutical dosage form of claim 9 which is in the form of a tablet comprising a film coating.

12. A method of treating a patient infected with hepatitis C virus comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 1.

13. The method of claim 12, wherein the pharmaceutical composition is administered for about 24 weeks or less.

14. The method of claim 12, wherein the pharmaceutical composition is administered for about 12 weeks or less.

15. The method of claim 12, wherein the pharmaceutical composition is administered for about 8 weeks or less.

16. The method of claim 12, wherein the pharmaceutical composition is administered for about 6 weeks or less.

17. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 12 weeks or less and wherein the hepatitis C virus is genotype 1, 2, 3, 4, 5, or 6.

18. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 8 weeks or less and wherein the hepatitis C virus is genotype 1, 2, 3, 4, 5, or 6.

19. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 6 weeks or less and wherein the hepatitis C virus is genotype 1, 2, 3, 4, 5, or 6.

20. The method of claim 17, 18, or 19, wherein the hepatitis C virus is genotype 1.

21. The method of claim 17, 18, or 19, wherein the hepatitis C virus is genotype 3.

22. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 12 weeks and wherein the hepatitis C virus is genotype 1a, 1b, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 5a, or 6a.

23. The method of claim 12, wherein the pharmaceutical composition is administered once daily for about 8 weeks and wherein the hepatitis C virus is genotype 1a, 1b, 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 3e, 3f, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 5a, or 6a.

24. The method of claim 12, further comprising administering ribavirin.

25. The method of claim 12, wherein the treatment does not include interferon.

26. The method of claim 12, wherein the treatment does not include ribavirin.

27. The method of claim 12, wherein the treatment does not include interferon or ribavirin.

28. The method of claim 12, further comprising administering an NS3 protease inhibitor.

29. The method of claim 12, further comprising administering simeprevir.

Dated this the 16th day of May, 2014.

Amrish Tiwari
Of K&S Partners
Attorney for the Applicant(s)